

Medical Journal of babylon, 7(3-4): 505-510. 2010

Procalcitonin as a Mediator of Chronic Inflammation in Obese Women with PCOS

Dr.Nadia Mudher Al-Hilli, FIBMS (OB/Gyn)

Dr. Haydar Hashim Al-Shalah, FIBMS (Clinical Path)

Babylon University/ College of Medicine/ Department of Obstetrics & Gynecology

Babylon University/ College of Medicine/ Department of Biochemistry

Background: Polycystic ovary syndrome (PCOS), a common reproductive endocrine condition characterized by hyperandrogenism, chronic anovulation, and obesity. Obesity is associated with a low-grade inflammation of white adipose tissue resulting from chronic activation of the innate immune system and can subsequently lead to insulin resistance, impaired glucose tolerance and even diabetes. In the last few years, adipose tissue emerged as an important source of proinflammatory mediators including TNF- α , IL-6, and procalcitonin.

Objective: to investigate procalcitonin as a marker of chronic inflammation in obese women with PCOS.

Method: a case control study conducted from January 2010 till July 2010. The study involved 20 women with PCOS & 20 control women matched for age & BMI. Waist to hip ratio was measured & blood was drawn from patients & controls & serum levels of FSH, LH, prolactin, testosterone & procalcitonin were estimated by VIDAS using VIDAS kits provided by Biomerieux (France). Student t test was used to evaluate the difference in serum procalcitonin level between the two groups.

Results: compared with control group, patients with PCOS had a high waist to hip ratio (mean 0.95 ± 0.2 versus 0.8 ± 0.13). Serum procalcitonin level was significantly higher in women with PCOS compared to control group (1.43 ± 0.42 ng/mL Vs 0.19 ± 0.13 ng/mL) P value was < 0.0001 . Serum levels of FSH, LH, prolactin & testosterone all were significantly higher in women with PCOS than in the control group (P value < 0.05).

Conclusion: The increase in low-grade chronic inflammation in women with PCOS is primarily associated with increased central fat excess. Procalcitonin represents a novel marker of the inflammatory activity of body fat in PCOS.

Introduction:

POLYCYSTIC OVARY SYNDROME (PCOS) is one of the most frequent endocrine disorders, affecting 5–10% of young women (1). In these patients, an increase in insulin resistance and in central body fat accumulation has been observed independent of obesity (1, 2, 3, 4). PCOS cases exhibit an adverse coronary heart disease (CHD) profile at an early age, including insulin resistance, dyslipidemia and increased central adiposity (5).

Low-grade chronic inflammation of white adipose tissue WAT, reflected by an increase in highly sensitive serum C-reactive protein (hs-CRP) is closely linked to insulin resistance, to central obesity, and to an increase in cardiovascular risk (6). WAT is the physiological site of energy storage as lipids. In addition, it has been more recently recognized as an active participant in numerous physiological and pathophysiological processes.

In obesity, WAT is characterized by an increased production and secretion of a wide range of inflammatory molecules including TNF-alpha and interleukin-6 (IL-6), which may have local effects on WAT physiology but also systemic effects on other organs. Recent data indicate that obese WAT is infiltrated by macrophages, which may be a major source of locally-produced pro-inflammatory cytokines. Interestingly, weight loss is associated with a reduction in the macrophage infiltration of WAT and an improvement of the inflammatory profile of gene expression. Several factors derived not only from adipocytes but also from infiltrated macrophages probably contribute to the pathogenesis of insulin resistance. Most of them are overproduced during obesity, including leptin, TNF-alpha, IL-6 and resistin. Conversely, expression and plasma levels of adiponectin, an insulin-sensitising effector, are down-regulated during obesity. Leptin could modulate TNF-alpha production and macrophage activation. TNF-alpha is overproduced in adipose tissue of several rodent models of obesity and has an important role in the pathogenesis of insulin resistance in these species. However, its actual involvement in glucose metabolism disorders in humans remains controversial. IL-6 production by human adipose tissue increases during obesity. It may induce hepatic CRP synthesis and may promote the onset of cardiovascular complications (7)

In patients with PCOS, circulating levels of TNF- α , IL-6, and hs-CRP as well as white blood cell count (WBC) and neutrophil count have been found to be elevated compared with age and/or body mass index (BMI)-matched controls (8,9,10).

When comparing patients with PCOS with controls, most previous studies adjusted differences in serum inflammatory markers for BMI or total fat mass. However, the impact of body fat distribution, *i.e.* the central accumulation of body fat, on these markers has never been assessed previously.

Waist to Hip Ratio

Waist-to-hip ratio (WHR) is a way of determining body shape (apple/pear) and thus weight-related health risks.

Apple-Shape or Pear-Shape:

Most people store their body fat in two distinct ways: around the middle (apple shape), or around the hips (pear shape).

For most people, being an apple shape (carrying extra fat around the abdomen) places them in a higher health risk category than being a pear shape (carrying extra weight around the hips or thighs). Other important measurements are Body Mass Index (BMI), Body Fat Percentage and Waist to hip ratio (11).

Aim of study: To assess serum procalcitonin as an inflammatory marker in patients with PCOS.

Patients & Method:

We consecutively recruited 20 patients diagnosed with PCOS who presented to our clinic and met the inclusion criteria. Twenty control women with regular menses were simultaneously recruited, with an attempt to match for BMI and age. The diagnosis of PCOS depended on the definition generated at the 2003 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop, which concluded that PCOS is a syndrome of ovarian dysfunction along with cardinal features of hyperandrogenism & polycystic ovary morphology and was based on a history of oligomenorrhea, oligoovulation &/or hirsutism with or without ultrasound evidence of polycystic ovaries (eight or more subcapsular follicular cyst ≥ 10 mm in diameter & increased ovarian stroma.) (12). None of the subjects had diabetes or evidence of cardiovascular disease, or infection and blood pressure was less than 140/90 mm Hg in all participants on screening examination. Subjects were screened by medical history and examination. Body weight & height were measured & BMI calculated. Waist to hip ratio was measured for all subjects. Blood samples were drawn on cycle day two in those with spontaneous menstrual cycles & on cycle day three of withdrawal bleeding induced by 10 mg daily of norethisterone acetate tablets for five days in those with amenorrhea or oligomenorrhea. Blood samples were immediately centrifuged, and serum was aliquoted and stored at -20°C until batch analyzed. FSH, LH, prolactin, testosterone & procalcitonin were estimated by VIDAS using VIDAS kits provided by Biomerieux (France).

Assay: The antigen is first captured by antibody present on solid phase. Enzyme linked antibody (conjugate) is then added making a sandwich like. Substrate that yields a fluorescent product on enzyme action is then added. The amount of light emitted from fluorescent product is directly proportional to the concentration of antigen present in the sample.

Ab + Ag + Enzyme linked Ab (conjugate) + fluorescent substrate

Statistical Analysis: For statistical analysis SPSS (version 10) program was used. The results were represented through mean & standard deviation. Student t-test used to compare between means & study the significance of the difference. P value <0.05 was considered to be statistically significant.

Results:

Table (1) shows the demographic of patients with PCOS & the control subjects. Age & BMI were comparable between the two groups waist to hip ratio was higher in PCOS patients (0.95 ± 0.2 Vs 0.8 ± 0.13) & the mean period of infertility was 2.6 years in these women.

Table (1) Demographic characteristics of the patients & controls.

character	PCOS patients (n=20) (mean \pm SD)	Control (n=20) (mean \pm SD)
Age (yr)	27 \pm 4.7	28.4 \pm 3.7
BMI (kg/m ²)	28.4 \pm 5.6	27.7 \pm 3.8
Waist-hip ratio	0.95 \pm 0.2	0.8 \pm 0.13
Period of infertility	2.6 \pm 1.6	1.6 \pm 0.4

Table (2) shows a comparison of the serum levels of FSH, LH, prolactin & testosterone between PCOS patients & controls. All of them were higher in patients than controls & by using student T test, the difference was statistically significant (P value < 0.05) .

Table (2) Hormonal assay of PCOS patients & control groups

Hormone	PCOS (n=20) (mean ± SD)	Control (n=20) (mean ± SD)	P value
FSH (mIU/ml)	5.25±2.5	6.8±2.8	0.037*
LH (mIU/ml)	9.1±4.3	2.52±0.98	0.0001*
Prolactin (ng/ml)	25.4±15.00	12.3±4.6	0.001*
Testosterone (ng/ml)	0.72±0.21	0.41±0.21	0.0001*

*significant P value < 0.05

Table (3) shows the difference in serum procalcitonin level in patients with PCOS & control subject. The level was significantly higher in PCOS patients (1.43± 0.42 Vs 0.19 ± 0.13). P value = 0.0001.

Table (3) Comparison of serum procalcitonin level in PCOS patients & control subjects.

Subjects	No.	Mean procalcitonin level (pg/ml)	SD(±)	Standard error of the mean	df	t	P value
PCOS patients	20	1.43	0.42	0.0094	19	14.95	0.0001*
control	20	0.19	0.13	0.0030	19		

* significant P value < 0.05

Discussion:

Subclinical inflammation and insulin resistance are important predictors of cardiovascular disease (13). In agreement with previous studies done by Kirchengast et.al & Ibanez et.al, (2, 3), we found that patients with PCOS had an excess of central fat independent of total fat mass reflected by higher waist to hip ratio when compared to normal subjects matched for BMI. Central fat excess is usually associated with an increase in serum inflammatory markers and in insulin resistance (14).

In our study we found that FSH, LH, prolactin & testosterone are all higher in patients with PCOS than in the control subjects This was in accordance with a study done by Zhonghua who found that FSH, LH, prolactin & testosterone were higher in obese women with PCOS when compared with non-obese PCOS patients & normal control subjects (15).

Also we found that serum procalcitonin was significantly higher in obese PCOS patients with central fat excess when compared to control subjects matched for BMI but with normal waist to hip ratio.

This result was similar to that found in a study done by Pudder et.al who measured procalcitonin & other inflammatory markers like TNF- α , C-reactive protein & white blood cells & found them to be significantly higher in obese women with PCOS compared to control group (16).

Another study done by Samy et.al. who investigated hormonal assay, lipid profile & inflammatory markers in obese & non-obese PCOS patients & compared them to control normal subjects, found that increased levels of testosterone, luteinizing hormone (LH), androstendione & insulin compared to healthy BMI matched controls. High-density lipoprotein (HDL) concentrations were significantly reduced in both patient groups compared to their controls, while triglyceride levels were significantly increased in obese group compared to controls. There is a significant increase in these markers when comparing obese PCOS patients and their matched controls (17).

Conclusion & Recommendations:

PCOS and obesity induce an increase in serum inflammatory cardiovascular risk markers. The precise mechanisms underlying these associations require additional studies to clarify the state of the cardiovascular system in women with PCOS compared with controls in large numbers of patients to determine the relative contribution of different factors including insulin resistance, androgen status and BMI.

References:

1. Ehrmann DA 2005 Polycystic ovary syndrome. *N Engl J Med* 352:1223–1236
2. Kirchengast S, Huber J 2004 Body composition characteristics and fat distribution patterns in young infertile women. *Fertil Steril* 81:539–544
3. Ibanez L, de Zegher F 2004 Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. *J Clin Endocrinol Metab* 89:1592–1597
4. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL 2003 Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. *Diabetologia* 46:625–633
5. Evelyn O Talbott, Jeanne Zborowski, Judy Rager. Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women? *Vasc Health Risk Manag.* 2008 April; 4(2): 453–462.
6. Forouhi NG, Sattar N, McKeigue PM 2001 Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. *Int J Obes Relat Metab Disord* 25:1327–1331
7. Bastard JP, Maachi M, Lagathu C. Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine Netw.* 2006 Mar;17(1):4-12.
8. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N 2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. *J Clin Endocrinol Metab* 86:2453–2455

9. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P 1999 Elevated serum levels of tumor necrosis factor α in normal-weight women with polycystic ovary syndrome. *Metabolism* 48:437–441
10. Sayin NC, Gucer F, Balkanli-Kaplan P, Yuce MA, Ciftci S, Kucuk M, Yardim T 2003 Elevated serum TNF- α levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. *J Reprod Med* 48:165–170
11. Anne Collins. ANNE COLLINS WEIGHT MANAGEMENT PROGRAM. 2007. internet.
12. Monga A. Disorders of menstrual cycle. *Gynaecology by Ten Teachers*. Hodder Arnold 18th edition 2006. Chapter 5, P 43-58.
13. **Frishman WH** 1998 Biologic markers as predictors of cardiovascular disease. *Am J Med* 104:18S–27S
14. **Wajchenberg BL** 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev* 21:697–738.
15. Zhonghua Yi Xue Za Zhi. Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome. 2005 Dec 7;85(46):3266-71.
16. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. *Journal of Clin Endocrinol Metab*. 2005 Nov;90(11):6014-21. 2005 Aug.
17. Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. *Dis Markers*. 2009;26(4):163-70.